Drugs / Tocotrienol-enriched Fraction of Palm Oil
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02142569 Comparator | Oct 2013 → Feb 2016 | low density lipoprotein cholesterol, mild elevation of | University of California, Los Angeles | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tocotrienol-enriched Fraction of Palm Oil | “Tocotrienol-enriched Fraction of Palm Oil (TRF)” NCT02142569 ↗ |
| Known as | TRF | “Tocotrienol-enriched Fraction of Palm Oil (TRF)” NCT02142569 ↗ |
| Action | Inhibit | “tocotrienol by suppressing the increase in gene expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA) reductase will further lower serum lipid compared to the CRYR alone.” NCT02142569 ↗ |
| Modality | Other / unclassified | “dietary supplement, the tocotrienol-enriched fraction of palm oil (TRF)” NCT02142569 ↗ |